Rivaroxaban Versus Warfarin and Renal Outcomes in Non-valvular Atrial Fibrillation Patients with Diabetes.
Vascular calcification is common in diabetic patients. Warfarin has been associated with renovascular calcification and worsening renal function; rivaroxaban may provide renopreservation by decreasing vascular inflammation. We compared the impact of rivaroxaban and warfarin on renal outcomes in diabetic patients with non-valvular atrial fibrillation (NVAF). Using US IBM MarketScan data from 1/2011-12/2017, we identified adults with both NVAF and diabetes, newly-initiated on rivaroxaban or warfarin with ≥12-months insurance coverage prior to anticoagulation initiation. Patients with stage 5 chronic kidney disease (CKD) or undergoing hemodialysis at baseline were excluded. Differences in baseline covariates between cohorts were adjusted using inverse probability-of-treatment weighting based on propensity scores (absolute standardized differences <0.1 achieved for all after adjustment). Outcomes included incidence rates of emergency department/hospital admissions for acute kidney injury (AKI) and the composite of the development of stage 5 CKD or need for hemodialysis. Patients were followed until an event, index anticoagulant discontinuation/switch, insurance disenrollment, or end-of-data availability. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox regression. We assessed 10,017 rivaroxaban (22·6% received a reduced dose) and 11,665 warfarin users. In comparison to warfarin, rivaroxaban was associated with lower risks of AKI (HR = 0·83, 95%CI=0·74-0·92) and development of stage 5 CKD or need for hemodialysis HR = 0·82, 95%CI=0·70-0·96). Sensitivity and subgroup analyses had similar effects as the base-case analysis. Rivaroxaban appears to be associated with lower risks of undesirable renal outcomes versus warfarin in diabetic NVAF patients.